A new Ebola virus study has shown promising preliminary results, preventing disease in infected nonhuman primates using monoclonal antibodies. When treatment was administered one hour after infection, all animals survived. Two-thirds of the animals were protected even when the treatment, known as MB-003, was administered 48 hours after infection.